Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in refractory melanoma. The company's pipeline is centered on RP1, making the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback